Therefore, miR-93-5p, as a circulating miRNA with multiple targets of immune checkpoints (including PD-L1, PD-L2, and B7-H6), has been considered to possess the potential in breast cancer immunotherapy, by a possible mechanism of reducing the expression of PD-L1, PD-L2, and B7-H6. The gene discussed is NCR3LG1; the disease is breast carcinoma.